In 2025, 19% of employers with 200+ workers reported covering GLP-1s for weight loss in their largest plan and coverage among the largest employers (5,000+ workers) rose to 43%
Drops in psoas muscle volume correlated with declines in intrahepatic triglycerides (rho = +0.32, P = 0.028), body mass index (rho = +0.31, P = 0.038), and the diabetes marker HbA1C (rho = +0.39, P = 0.007)
Clear instruction on injection technique reduces preventable irritation and improves adherence
These challenges drive people to seek alternatives that provide the same medication at lower costs or with better availability
Risks specific to compounded sources: potency variation (compounded preparations are not subject to the same batch consistency testing as manufactured drugs), sterility concerns if quality controls are inadequate, and no systematic post-market safety monitoring
Tirzepatide begins reducing appetite within 3-7 days, whereas diet changes require weeks of conscious effort before neural appetite pathways adapt